Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250389 | 0.92 | MAPK1 (0.38) | TSHRL3MBTL1MAPK1LMNAHTT | |
| SCHEMBL4097495 | 0.85 | TSHR (0.39) | TSHRL3MBTL1MAPK1HTTALDH1A1 | |
| SCHEMBL10207850 | 0.79 | MGAM (0.34) | TSHRMAPK1LMNAALDH1A1KMT2A | |
| SCHEMBL3256641 | 0.77 | KMT2A (0.32) | TSHRL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL714250 | 0.74 | EPHX1 (0.37) | — | |
| SCHEMBL10207853 | 0.73 | MAPK1 (0.36) | TSHRMAPK1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL17048959 | 0.72 | TSHR (0.37) | TSHRL3MBTL1MAPK1LMNAHTT | |
| SCHEMBL13358783 | 0.72 | — | — | |
| SCHEMBL712577 | 0.71 | EPHX1 (0.30) | — | |
| SCHEMBL6329063 | 0.69 | LMNA (0.33) | MAPK1LMNAALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | MIYAZAWA SHUHEI | 2009-08-13 | — | — | US | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | HRH2, HRH4, HRH1 | TSHR 791/4885L3MBTL1 299/4885MAPK1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.